What's New
FTD in the News
Amylyx Pharmaceuticals Ends PSP Trial of AMX0035
Amylyx Pharmaceuticals announced recently that it would end its phase 2b trial of its drug AMX0035 for…
Tenacious AFTD Advocacy Gaining Momentum
With 2025’s FTD Awareness Week now behind us, AFTD’s Advocacy team is already gearing up its efforts…
The New York FTD Registry: How Advocacy Drives Change
The International Business Times UK recently drew an important connection between FTD advocacy efforts and the new…
AFTD and ADDF Award $2.5 million to Vesper Biotechnology for Drug VES001 Clinical Trial in FTD
The Association for Frontotemporal Degeneration (AFTD) and the Alzheimer’s Drug Discovery Foundation (ADDF) recently awarded $2.5 million…
AFTD Ambassador and “Protective Mama Bear” Dawn Kirby Interviewed on Podcast
Dawn Kirby’s daughter Kara was diagnosed with FTD at age 29. In a recent episode of the…
A Rose with Pink Petals: How FTD Revealed Deb Jobe’s Hidden Artist
Deb Jobe, co-chair of the AFTD Persons with FTD Advisory Council, was featured in the journal Brain…
